EP3419661A4 - METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LUNGIONS WITH A VACCINATE - Google Patents

METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LUNGIONS WITH A VACCINATE Download PDF

Info

Publication number
EP3419661A4
EP3419661A4 EP17757336.7A EP17757336A EP3419661A4 EP 3419661 A4 EP3419661 A4 EP 3419661A4 EP 17757336 A EP17757336 A EP 17757336A EP 3419661 A4 EP3419661 A4 EP 3419661A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
composition
treating cancer
skin injury
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17757336.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3419661A1 (en
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of EP3419661A1 publication Critical patent/EP3419661A1/en
Publication of EP3419661A4 publication Critical patent/EP3419661A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EP17757336.7A 2016-02-27 2017-02-24 METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LUNGIONS WITH A VACCINATE Pending EP3419661A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (2)

Publication Number Publication Date
EP3419661A1 EP3419661A1 (en) 2019-01-02
EP3419661A4 true EP3419661A4 (en) 2019-10-23

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17757336.7A Pending EP3419661A4 (en) 2016-02-27 2017-02-24 METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LUNGIONS WITH A VACCINATE

Country Status (16)

Country Link
EP (1) EP3419661A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019506435A (cg-RX-API-DMAC10.html)
KR (1) KR102873848B1 (cg-RX-API-DMAC10.html)
CN (2) CN122399006A (cg-RX-API-DMAC10.html)
AU (1) AU2017223970B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018067550A2 (cg-RX-API-DMAC10.html)
CA (1) CA3015519A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018002438A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018009205A2 (cg-RX-API-DMAC10.html)
HK (1) HK1256935A1 (cg-RX-API-DMAC10.html)
IL (1) IL261340B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018010338A (cg-RX-API-DMAC10.html)
MY (1) MY194694A (cg-RX-API-DMAC10.html)
SG (1) SG11201807080UA (cg-RX-API-DMAC10.html)
WO (1) WO2017147475A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201805679B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
ES2962700T1 (es) * 2020-10-12 2024-03-20 Hpvvax Llc Composición y método para tratar el cáncer, usando una vacuna como un primer ingrediente activo terapéutico en combinación con un segundo ingrediente activo
CN120302980A (zh) * 2022-10-31 2025-07-11 皮洛杰斯股份有限公司 免疫疗法组合物和使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20130251782A1 (en) 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) * 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. SCHILLING ET AL: "Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines", PEDIATRICS, vol. 136, no. 3, 1 September 2015 (2015-09-01), pages e563 - e572, XP055519294, ISSN: 0031-4005, DOI: 10.1542/peds.2014-4199 *
ANNA J. NICHOLS ET AL: "Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine to Treat Multiple Cutaneous Basaloid Squamous Cell Carcinomas", JAMA DERMATOLOGY, vol. 154, no. 8, 1 August 2018 (2018-08-01), US, pages 927, XP055537673, ISSN: 2168-6068, DOI: 10.1001/jamadermatol.2018.1748 *
ANNA TADDIO ET AL: "A randomized controlled trial of analgesia during vaccination in adults", VACCINE, vol. 28, no. 32, 1 July 2010 (2010-07-01), AMSTERDAM, NL, pages 5365 - 5369, XP055620773, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2010.05.015 *
GARLAND SUZANNE M ET AL: "Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine", VACCINE, vol. 33, no. 48, 3 August 2015 (2015-08-03), pages 6855 - 6864, XP029332047, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2015.08.059 *
See also references of WO2017147475A1 *

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
AU2017223970A1 (en) 2018-09-13
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
KR102873848B1 (ko) 2025-10-17
MX2018010338A (es) 2018-11-09
JP2019506435A (ja) 2019-03-07
CN108883168A (zh) 2018-11-23
AU2017223970B2 (en) 2022-01-27
CO2018009205A2 (es) 2018-09-20
EP3419661A1 (en) 2019-01-02
MY194694A (en) 2022-12-15
KR20180112043A (ko) 2018-10-11
CN122399006A (zh) 2026-07-17
JP7732784B2 (ja) 2025-09-02
ZA201805679B (en) 2019-11-27
BR112018067550A2 (pt) 2019-10-01
CA3015519A1 (en) 2017-08-31
CL2018002438A1 (es) 2019-01-04
JP2021155448A (ja) 2021-10-07
HK1256935A1 (zh) 2019-10-04
JP2023110038A (ja) 2023-08-08
SG11201807080UA (en) 2018-09-27
WO2017147475A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating alzheimer's disease
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
IL262763A (en) Preparations and methods for treating Huntington's disease
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA45406A (fr) Inhibiteurs d'ezh2 pour traiter le cancer
EP3510161A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
EP3359662A4 (en) COMPOSITIONS AND METHODS OF TREATING HUNTINGTON DISEASE AND RELATED DISEASES
EP3320093A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING AND TREATING CANCER USING SLNCR ISOFORMS
EP2978450A4 (en) METHOD FOR INCREASING THE EFFICACY OF A SURVIVIN VACCINE FOR THE TREATMENT OF CANCER
MA45054A (fr) Conjugués médicament-anticorps dll3 pour le traitement de tumeurs à risque de transition neuroendocrinienne
EP3668500A4 (en) METHOD OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
EP3291842A4 (en) SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER
IL263433A (en) Methods for treating alzheimer's disease
EP3502807A4 (en) METHOD AND DEVICE FOR SUPPORTING HUMAN-MACHINE INTERACTION
EP3782618A4 (en) METHODS OF PREVENTING OR TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
IL283833A (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
EP3400008A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEPATITIS B
EP3725326A4 (en) METHODS AND MEDICINAL PRODUCTS FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS
EP3426802A4 (en) IN-SILICO PROCESS FOR THE SELECTION OF AUXILIARY SUBSTANCES FOR PROTEIN FORMULATIONS
EP3638270A4 (en) COMPOSITIONS AND PROCEDURES FOR IMPROVING HYPERTHERMAL THERAPY
PL3585373T3 (pl) Związki do stosowania w sposobach leczenia choroby Alzheimera
EP3429569A4 (en) METHOD FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY PARNY SYNTHESIS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190925

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101AFI20190919BHEP

Ipc: A61P 35/00 20060101ALI20190919BHEP

Ipc: C12N 7/00 20060101ALI20190919BHEP

Ipc: C07K 14/005 20060101ALI20190919BHEP

Ipc: A61P 31/20 20060101ALI20190919BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201028